ロード中...
Novel ligands that target the mitochondrial membrane protein mitoNEET
Ligands of the thiazolidinedione (TZD) class of compounds, pioglitazone (Actos™) and rosiglitazone (Avandia™) are currently approved for treatment of type 2 diabetes and are known to bind to the PPAR-γ nuclear receptor subtype. Recent evidence suggesting PPAR-γ independent action of the TZDs led to...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2011
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3477874/ https://ncbi.nlm.nih.gov/pubmed/21531159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jmgm.2011.04.001 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|